Practice Signal

MASH/MASLD Pharmacotherapy

GI/Hepatology 10 sources

Evidence at a Glance

Source	Grade / Verdict
Semaglutide Improves MASH Histology in Phase 3 ESSENCE Interim Study · New England Journal of Medicine	Grade: High Practice-changing
Resmetirom Achieves Dual Histologic Endpoints in NASH Fibrosis Study · The New England Journal of Medicine	Grade: High Practice-changing
Tirzepatide Resolves MASH but Fibrosis Benefit Unproven in Phase 2 Study · The New England Journal of Medicine	Grade: Moderate Hypothesis-generating
Survodutide Improves MASH Histology Across Doses in Phase 2 Study · The New England Journal of Medicine	Grade: Moderate Hypothesis-generating
AASLD Adds Semaglutide to MASH Practice Guidance With NIT-Based Selection Guideline · Hepatology (Baltimore, Md.)	Grade: Moderate Practice-changing
EASL-EASD-EASO Guidelines Redefine MASLD Care With Resmetirom Entry Guideline · Journal of Hepatology	Grade: Moderate Practice-changing
Semaglutide 2.4 mg: Cost-Effective MASH Treatment Study · PharmacoEconomics
Resmetirom Efficacy Holds With GLP-1 or SGLT2 Background; Weight Loss Amplifies It Study · Alimentary Pharmacology & Therapeutics	Grade: Moderate Confirmatory
Resmetirom Update: Positioning the First Approved MASH Therapy Study · Drug Design, Development and Therapy	Grade: Moderate Confirmatory
Resmetirom Introduces New Hope for MASH Treatment Study · Nature Reviews. Drug Discovery

🔒

Practice Recommendations: Subscribers Only

The bedside actions and open questions that turn this evidence into practice.

Practice Considerations: the bedside actions

Open Questions & evidence gaps

Want the full review?

Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.

Become a Subscriber →

🎓

Synthesized and reviewed by a licensed pharmacist

Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.

Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.

Thanks for the feedback!

← Back to Evidence Rounds